C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · IEX Real-Time Price · USD
5.68
-0.29 (-4.86%)
At close: May 17, 2024, 4:00 PM
5.69
+0.01 (0.18%)
After-hours: May 17, 2024, 7:54 PM EDT
C4 Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for C4 Therapeutics stock have an average target of 8.88, with a low estimate of 2.00 and a high estimate of 16. The average target predicts an increase of 56.34% from the current stock price of 5.68.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CCCC stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 4 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +40.85% | May 9, 2024 |
| Stifel | Stifel | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +146.48% | May 9, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $1 → $8 | Hold | Maintains | $1 → $8 | +40.85% | Feb 26, 2024 |
| Stifel | Stifel | Strong Buy Reiterates $12 → $13 | Strong Buy | Reiterates | $12 → $13 | +128.87% | Feb 23, 2024 |
| JP Morgan | JP Morgan | Sell → Hold Upgrades $6 | Sell → Hold | Upgrades | $6 | +5.63% | Jan 29, 2024 |
Financial Forecast
Revenue This Year
27.37M
from 20.76M
Increased by 31.87%
Revenue Next Year
21.88M
from 27.37M
Decreased by -20.06%
EPS This Year
-1.89
from -2.67
EPS Next Year
-1.96
from -1.89
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 48.3M | 52.5M | 495.5M | 4.7B | 13.5B |
| Avg | 27.4M | 21.9M | 155.9M | 1.2B | 3.3B |
| Low | n/a | n/a | n/a | n/a | 26.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 132.7% | 91.8% | 2,164.6% | 2,928.4% | 1,066.8% |
| Avg | 31.9% | -20.1% | 612.3% | 643.0% | 187.3% |
| Low | - | - | - | - | -97.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.13 | -0.85 | -0.36 |
| Avg | -1.89 | -1.96 | -1.26 |
| Low | -2.47 | -2.95 | -1.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.